Pfizer Inc. said Friday that its experimental rheumatoid arthritis drug met the main goals of a late-stage clinical trial, a welcome boost for the world’s largest drugmaker as it seeks new products to offset those losing patent protection.
The drug, tofacitinib, is one of the most important in Pfizer’s pipeline. The company said the safety profile of the drug was consistent with that seen in the clinical program, and no new safety signals were seen. Get the full story »
